Altimmune Raises $75M via Dilutive Offering at Significant Discount to Fund Clinical Trials

summarizeSummary

Altimmune announced a $75 million registered direct offering at a deep discount, leading to significant shareholder dilution, to fund its clinical development programs, with further capital raises anticipated.

check_boxKey Events

• Registered Direct Offering Priced

  Altimmune will sell 12,397,920 shares of common stock and pre-funded warrants to purchase 4,647,534 shares, totaling $75 million in gross proceeds.

• Significant Discount to Market

  The offering price of $4.40 per share represents a 28.7% discount compared to the common stock's closing price of $6.18 on January 27, 2026.

• Substantial Shareholder Dilution

  The offering will result in approximately 15.1% dilution to existing shareholders, with 17,045,454 new shares (including warrants) being issued.

• Proceeds for Clinical Development

  Net proceeds of approximately $70.4 million are earmarked for advancing clinical development of pipeline candidates, particularly the Phase 3 trial for pemvidutide in MASH, and general corporate purposes.

auto_awesomeAnalysis

Altimmune, Inc. has finalized a registered direct offering to raise $75 million through the sale of common stock and pre-funded warrants. The offering is priced at $4.40 per share, representing a substantial 28.7% discount to the common stock's closing price of $6.18 on January 27, 2026. This transaction will result in significant dilution, adding 17,045,454 shares (including those underlying warrants) to the 112,833,597 shares outstanding, representing approximately 15.1% dilution to existing shareholders. While the proceeds are intended to fund critical clinical development, including the upcoming Phase 3 trial for pemvidutide in MASH, the company explicitly states that these funds will be insufficient to complete these trials, indicating a need for further capital raises and potential future dilution.